Sector News

Biopharma’s 10 highest-paid heads of R&D

August 28, 2015
Life sciences

Last year’s hyperbole-straining biopharma boom saw 41 drug approvals, a class dotted with projected blockbusters whose debut sent market caps around the industry soaring to unprecedented heights. And that hot streak trickled down to the industry’s best-compensated scientists, as the virtuous cycle of ever-climbing valuations helped line the pockets of biopharma’s R&D leaders.

The year’s 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013’s top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma’s macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.

Take, for example, Gilead Sciences ($GILD) Chief Scientific Officer Norbert Bischofberger. As a reward for his leadership in developing the drugs that became Harvoni and Zydelig, Gilead dialed up his stock awards and incentive pay, making for a whopping 21.5% raise and gross take-home of $8.3 million.

But Bischofberger didn’t make this list.

And neither did Amgen’s ($AMGN) Sean Harper, Novartis’ ($NVS) Mark Fishman nor GlaxoSmithKline’s ($GSK) Moncef Slaoui, a trio of mainstays whose nothing-to-scoff-at paychecks were usurped by younger companies promising big payouts as they take a page from Big Pharma and diversify their pipelines.

This year’s top 10 is, across the board, noticeably light on multinational pharma giants. That’s in part because, f​or reasons including legal obligation and continental custom, the likes of AstraZeneca ($AZN), Sanofi ($SNY) and Roche ($RHHBY) don’t disclose what they pay their top researchers. But it also reflects the continued rise of biopharma’s middle class, as former upstarts like Regeneron ($REGN), Biogen ($BIIB) and Alexion ($ALXN) are contending with–and outspending–traditional powerhouses.

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.